Holen Sie sich die Stockscreener-App
1.03
0.00%
0.00
Handel nachbörslich:
1.02
-0.01
-0.97%
Schlusskurs vom Vortag:
$1.03
Offen:
$1.03
24-Stunden-Volumen:
1.97M
Relative Volume:
0.37
Marktkapitalisierung:
$301.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-3.8148
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
+7.48%
1M Leistung:
-9.65%
6M Leistung:
+46.58%
1J Leistung:
-21.97%
1-Tages-Spanne:
$1.03
$1.0693
1-Wochen-Bereich:
$0.945
$1.0693
52-Wochen-Spanne:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.03 | 301.07M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen reports EMA positive advice for acceptability of OCU410ST - MSN
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen
Ocugen, Inc. Announces Positive Scientific Advice from the Europ - GuruFocus
Ocugen gets EMA backing for single trial of Stargardt disease therapy - Investing.com Australia
Ocugen, Inc. Announces Positive Scientific Advice from the - GlobeNewswire
Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan - Stock Titan
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Janus Henderson Group Plc shares rise 1.98% after-hours following $20 million investment in Ocugen, Inc. - AInvest
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen raises $20 million in direct offering to Janus Henderson - Investing.com
Ocugen raises $20 million in direct offering to Janus Henderson By Investing.com - Investing.com Australia
Ocugen Secures $20 Million in Registered Direct Offering, Extending Cash Runway into 2026 - AInvest
Ocugen secures crucial $20M funding from Janus Henderson, could unlock additional $30M from warrants - Stock Titan
Ocugen Announces $20M Securities Purchase Agreement to Bolster Gene Therapy Programs - AInvest
Will Ocugen Inc. Benefit From Broader Market BounceMarket Momentum and Signal Alerts Suggest Reversal - beatles.ru
Ocugen Announces $20M Securities Purchase Agreement - TipRanks
Ocugen Announces $20 Million Registered Direct Offering of Common Stock and Warrants. - AInvest
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What are the technical indicators suggesting about Ocugen Inc.Free Stock Market Mentorship - Jammu Links News
Is it the right time to buy Ocugen Inc. stockSuperior returns - Jammu Links News
What are Ocugen Inc. company’s key revenue driversGet alerts on the hottest stocks daily - Jammu Links News
What catalysts could drive Ocugen Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
What markets is GWH.WS expanding into Is Ocugen Inc. stock a good long term investment option - Jammu Links News
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials - MSN
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):